2009-2018年美国急性心肌梗死合并心源性休克多支冠状动脉病变患者的血运重建实践与结局
该队列研究基于美国CathPCI注册研究,纳入2009年7月1日至2018年3月31日期间1649家医院的64301例急性心肌梗死合并心源性休克且有多支冠状动脉病变并接受PCI的患者。34.9%接受了初次多支血管PCI,在STEMI亚组(48943例)中为31.5%,2009至2018年间该比例在AMI中每年增加6.7%、在STEMI中每年增加5.8%。多支血管PCI与更高的调整后住院并发症风险相关(OR 1.18,95%CI 1.14-1.23),在STEMI患者中与更高的住院死亡率相关(OR 1.11,95%CI 1.06-1.16)。在Medicare受益人中,多支血管PCI与出院后1年死亡率无关(51.5% vs 49.8%;风险调整OR 0.97,95%CI 0.90-1.04;P=0.37)。医院间多支血管PCI使用率存在显著差异(中位OR 1.37,95%CI 1.33-1.41),STEMI PCI使用率高的医院风险调整住院死亡率更高(最高 vs 最低医院多支血管PCI四分位:OR 1.10,95%CI 1.02-1.19)。
要点
- 在AMI合并心源性休克的多支病变患者中,多支血管PCI与更高的调整后住院并发症风险相关(OR 1.18,95%CI 1.14-1.23)。
- 在STEMI亚组中,多支血管PCI与更高的住院死亡率相关(OR 1.11,95%CI 1.06-1.16)。
- 2009至2018年间多支血管PCI使用率在AMI中每年增加6.7%、在STEMI中每年增加5.8%。
- 在Medicare受益人中,多支血管PCI与出院后1年死亡率无关(51.5% vs 49.8%;风险调整OR 0.97,95%CI 0.90-1.04;P=0.37)。
- STEMI PCI使用率高的医院(最高 vs 最低多支血管PCI四分位)风险调整住院死亡率更高(OR 1.10,95%CI 1.02-1.19)。
适用人群与场景
- 美国CathPCI注册研究中2009年7月1日至2018年3月31日期间因急性心肌梗死合并心源性休克、有多支冠状动脉病变并接受PCI的患者,共64301例,来自1649家美国医院。
- STEMI亚组共48943例。
- Medicare受益人亚组用于评估出院后结局。
研究设计与关键结果
- 研究类型:队列研究,基于美国CathPCI注册研究,纳入1649家美国医院的64301例患者(平均[SD]年龄66.4[12.5]岁;20366例[31.7%]女性;54538例[84.8%]白人)。
- 暴露:多支血管PCI vs 罪犯血管PCI。
- 主要终点为住院死亡率;34.9%接受初次多支血管PCI,STEMI亚组(48943例)中31.5%接受多支血管PCI。
- 2009至2018年间多支血管PCI比例在AMI中每年增加6.7%、在STEMI中每年增加5.8%。
- 多支血管PCI与更高的调整后住院并发症风险相关(OR 1.18,95%CI 1.14-1.23),在STEMI患者中与更高的住院死亡率相关(OR 1.11,95%CI 1.06-1.16)。
- Medicare受益人中,多支血管PCI与出院后1年死亡率无关(51.5% vs 49.8%;风险调整OR 0.97,95%CI 0.90-1.04;P=0.37)。
- 医院间多支血管PCI使用率存在显著差异(中位OR 1.37,95%CI 1.33-1.41);STEMI PCI使用率高的医院风险调整住院死亡率更高(最高 vs 最低医院多支血管PCI四分位:OR 1.10,95%CI 1.02-1.19)。
证据类型、等级与局限
- 证据类型:基于美国CathPCI注册研究的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,随着近期证据提示多支血管PCI策略可能有害,亟需改变实践并改善这一高危人群的结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Cardiogenic shock after acute myocardial infarction (AMI) is associated with high mortality, particularly among patients with multivessel coronary artery disease. Recent evidence suggests that use of multivessel percutaneous coronary intervention (PCI) may be associated with harm. However, little is known about recent patterns of care and outcomes for this patient population.
OBJECTIVE: To evaluate patterns in the use of multivessel PCI vs culprit-vessel PCI in AMI and cardiogenic shock and outcomes in the US from 2009 to 2018.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study identified all patients in the CathPCI Registry) with AMI and cardiogenic shock who had multivessel coronary artery disease and underwent PCI between July 1, 2009, and March 31, 2018.
EXPOSURES: Multivessel or culprit-vessel PCI for AMI and shock.
PRIMARY OUTCOMES AND MEASURES: The primary outcome was in-hospital mortality. Temporal trends and hospital variation in PCI strategies were evaluated, while accounting for differences in case mix using hierarchical models. As a secondary outcome, the association of PCI strategy with postdischarge outcomes was evaluated in the subset of patients who were Medicare beneficiaries.
RESULTS: Of 64 301 patients (mean [SD] age, 66.4 [12.5] years; 20 366 [31.7%] female; 54 538 [84.8%] White) with AMI and shock at 1649 US hospitals, 34.9% had primary multivessel PCI. In the subgroup of 48 943 patients with ST-segment elevation myocardial infarction (STEMI), 31.5% underwent multivessel PCI. Between 2009 and 2018, this percentage increased by 6.7% per year for AMI and 5.8% for STEMI. Overall, multivessel PCI was associated with a greater adjusted risk of in-hospital complications (odds ratio [OR], 1.18; 95% CI, 1.14-1.23) and with greater in-hospital mortality in patients with STEMI (OR, 1.11; 95% CI, 1.06-1.16). Among Medicare beneficiaries, multivessel PCI use was not associated with postdischarge 1-year mortality (51.5% vs 49.8%; risk-adjusted OR, 0.97; 95% CI, 0.90-1.04; P = .37). Significant hospital variation was found in the use of multivessel PCI, with a higher multivessel PCI rate for similar patients across hospitals (median OR, 1.37; 95% CI, 1.33-1.41). Patients at hospitals with high rates of PCI in STEMI use had higher risk-adjusted in-hospital mortality (highest vs lowest hospital multivessel PCI quartile: OR, 1.10; 95% CI, 1.02-1.19).
CONCLUSIONS AND RELEVANCE: This cohort study found that multivessel PCI was increasingly used as the revascularization strategy in AMI and shock and that hospitals that used multivessel PCI more, especially among patients with STEMI, had worse outcomes. With recent evidence suggesting harm with this strategy, there appears to be an urgent need to change practice and improve outcomes in this high-risk population.
参考来源
- Khera R, Secemsky EA, Wang Y, et al. Revascularization Practices and Outcomes in Patients With Multivessel Coronary Artery Disease Who Presented With Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018. JAMA Intern Med. 2020. PMID: 32833024. doi:10.1001/jamainternmed.2020.3276
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。